Influenza Vaccines Market

Influenza Vaccines Market Market Synopsis The influenza virus causes a contagious respiratory ailment called influenza. Influenza is marked by fever, cough, muscle and joint discomfort, headache, and extreme weakness.

Influenza illness may vary from mild to severe and can even result in death. According to the World Health Organization (WHO), influenza-related hospitalizations varied from 3-5 million instances for severe illness in 2018, while influenza-related fatalities ranged from 290,000 to 650,000.

Vaccinations are advised for the prevention of influenza illnesses. Inactivated influenza vaccines, adjuvant inactivated influenza vaccines, live attenuated influenza vaccines, and recombinant influenza vaccines are all types of influenza vaccines. The increasing expansion of influenza virus outbreaks throughout the globe is driving demand for effective influenza vaccinations. A robust product pipeline will be the primary driver of market growth during the projection period.

Download Free PDF Sample: Click Here Market Size and Growth Analysis As per DataM Intelligence’s new proven results, the “Global Influenza Vaccines Market” reached US$ 6.4 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 10.8 billion by 2030. The global influenza vaccines market is expected to exhibit a CAGR of 6.9% during the forecast period 2023-2030.

Influenza Vaccines Market: Drivers Rising Number of Government Investments The rising number of government investments is one of the significant factors assisting the market's future growth. For example, in March 2022, the Australian government contributed more than $100 million to the seasonal influenza vaccination to safeguard individuals at risk.

Furthermore, large pharmaceutical companies are devoting substantial money and effort to developing improved medicine in the form of vaccines.

For example, Seqirus invested in Next-generation influenza vaccine technology, selfamplifying mRNA, in August 2021. The company intended to begin clinical trials for both seasonal and pandemic influenza vaccines.

R&D Investments with A Strong Pipeline R&D expenditures with a solid pipeline assist the market development during the projection period. Leading market players, such as CSL Limited, Sanofi, and GlaxoSmithKline plc, are boosting R&D investment to enhance manufacturing capacity and concentrate on creating innovative vaccines, propelling the industry ahead.

Segmentation Analysis

The global influenza vaccines market is segmented by vaccine type, virus type, age group, and region.

By Vaccine Type • •

Quadrivalent Trivalent Vaccines

By Virus Type • •

Type A Influenza Virus Type B Influenza Virus

By Age Group • •

Children Adult

By Region • • • • •

North America Latin America Europe Asia Pacific Middle East, and Africa

Based on Vaccine Type: Quadrivalent Vaccines to Ace the Market Due to Growing Efficacy The Quadrivalent from the vaccine segment is predicted to dominate over the projection period with roughly 54.3%. The quadrivalent influenza vaccine is designed to protect against four different influenza viruses, two of which are influenza A and influenza B. The quadrivalent segment is expected to dominate the influenza vaccine market due to its low cost, efficacy against viral infections, and simplicity of availability in hospitals and clinics. Product approvals for quadrivalent vaccinations are also expected to drive market growth.

For example, the US FDA approved GlaxoSmithKline's Fluarix, a quadrivalent influenza vaccine, in July 2022. The Fluarix quadrivalent vaccine is designed for active immunization to prevent illness caused by the vaccine's influenza A and B subtype viruses.

For more detailed information: Click Here Recent Industry News •

•

In July 2023, Sinovac Biotech Ltd. announced an alliance with Indonesian state-owned biopharmaceutical company PT Bio Farma to serve Indonesia's domestic vaccine market as well as the international market.

In May 2023, CureVac announced the start of phase 1/2 seasonal influenza vaccine trial.CureVac has announced that the first participant has been dosed in the initial

•

phase of a combined phase 1/2 study of its multivalent mRNA seasonal influenza vaccine candidates, developed in collaboration with GSK. In August 2022, Roche announced the approval of an influenza medication as well as a new COVID test. The FDA has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years old who have been symptomatic for no more than 48 hours.

Regional Analysis North America is Expected to Hold a Dominant Position Among all regions, North America is likely to have a dominating position in the market throughout the forecast period owing to the government agencies in the United States being focused on partnerships to expand the supply of influenza vaccinations.

For example, as part of an inter-agency government effort in the United States, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) are collaborating to develop new and better influenza vaccines.

Furthermore, the Advisory Council on Immunization Practices recommends influenza vaccination in order to reduce the disease's large annual health impact.

Market Leaders in the Global Influenza Vaccines Market • • • • • • • • • •

AstraZeneca PLC CSL Limited Abbott Laboratories F.Hoffmann-La Roche Ltd Emergent BioSolutions GlaxoSmithKline PLC Gamma Vaccines Pvt Ltd Merck & Co Pfizer Inc Sanofi Pasteur SA

About DataM Intelligence DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We at DataM Intelligence leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of Syndicate Reports & and; Customized Reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies

across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.

Media Contact Company Name: DataM Intelligence Contact Person: Sai.K Email: Send Email Phone: +1 877 441 4866 Website: https://www.datamintelligence.com/